Carlo Castellani Genova, 07/02/2024

CURRICULUM VITAE

Nome e Cognome	Carlo Castellani
Indirizzo lavorativo	
Domicilio	
Telefono lavoro	
E-Mail	
Posizione funzionale attuale	Responsabile UOSD Fibrosi Cistica, Istituto G Gaslini
Incarichi precedenti	Incarichi precedenti presso il Centro Fibrosi Cistica dell'Azienda Ospedaliera Universitaria Integrata di Verona: Incarico di Alta Specializzazione "Screening neonatale e consulenza genetica" Incarico dirigenziale di struttura semplice funzionale "Centro Adulti" Incarico Professionale Funzionale "Centro Adulti"
In servizio presso	Centro Fibrosi Cistica, Istituto Gaslini, Via G Gaslini 5, 16147 Genova
Titoli di Studio	Maturità classica Liceo Scipione Maffei Verona Laurea in Medicina e Chirurgia presso l'Università di Verona nel 1985 Specializzazione in Pediatria presso l'Università di Verona nel 1989 Specializzazione in Genetica Medica presso l'Università di Verona nel 1994
Carriera lavorativa	Medico frequentatore presso la Clinica Pediatrica dell'Ospedale Policlinico di Verona dal 11-12-85 al 14-05-89. Assistente medico, disciplina pediatria di ruolo, con rapporto di lavoro a tempo pieno, presso il reparto di Pediatria dell'Ospedale di Bussolengo (VR) dal 15-5-89 al 7-9-93. Assistente medico, disciplina pediatria di ruolo, con rapporto di lavoro a tempo pieno, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 8-9-93 al 29-12-93. Primo livello dirigenziale Fascia Sub B Assistente Medico, disciplina pediatria di ruolo, con rapporto di lavoro a tempo pieno, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 30-12-93 al 14-5-94. Primo livello dirigenziale Fascia Sub B Assistente Medico Ex Art.117, disciplina pediatria di ruolo, con rapporto di lavoro a tempo pieno, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 15-5-94 al 5-12-96. Dirigente Medico I livello, disciplina pediatria a tempo indeterminato, con rapporto di lavoro a tempo unico, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 6-12-96 al 30/7/1999.

	Dirigente Medico a rapporto esclusivo, disciplina pediatria a tempo indeterminato, con rapporto di lavoro a tempo unico, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 31/7/1999 al 31/12/2004. Dirigente Medico a rapporto esclusivo, Incarico di Alta Professionalità, disciplina pediatria a tempo indeterminato, con rapporto di lavoro a tempo unico, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 1/1/2005 al 10/8/2008. Dirigente Medico a rapporto esclusivo, Incarico di direzione struttura semplice funzionale, disciplina pediatria a tempo indeterminato, con rapporto di lavoro a tempo unico, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 11/8/2008 al 30/6/2013. Dirigente Medico a rapporto esclusivo, Incarico professionale funzionale, disciplina pediatria a tempo indeterminato, con rapporto di lavoro a tempo unico, presso il Centro Fibrosi Cistica dell'Ospedale Civile Maggiore di Verona dal 1/7/2013 al 30/06/2018. Dirigente medico a tempo pieno, determinato presso l'UOSD del Centro Fibrosi Cistica dell'Istituto Gaslini, con sede in via Gerolamo Gaslini 5, Genova dal 1/07/2018 al 31/12/2018. Dirigente medico a tempo pieno, indeterminato e Direttore UOSD Centro Fibrosi Cistica dell'Istituto Gaslini, con sede in via Gerolamo Gaslini 5, Genova dal 1/01/2019 a tutt'oggi.
Ambiti di autonomia professionale	- Responsabile del Servizio Clinico di Screening Neonatale per la Fibrosi Cistica del Centro Fibrosi Cistica dell'Ospedale Civile Maggiore (delibera del Direttore Generale dell'Azienda Ospedaliera di Verona 1709 del 28-7-97). Il ruolo implica: una stretta collaborazione con il Laboratorio di Patologia Molecolare all'interno del Laboratorio Analisi dell'Ospedale Civile Maggiore; la collaborazione con i punti nascita delle regioni Veneto e Trentino-Alto Adige per la corretta raccolta dei campioni e l'interpretazione di situazioni particolari; la gestione dei neonati positivi allo screening neonatale e la diagnostica differenziale tra falsi positivi e veri positivi (affetti da fibrosi cistica); la comunicazione di diagnosi; la gestione del servizio di segreteria per Screening Neonatale e Consulenza Genetica. - Responsabile della struttura semplice adulti all'interno del Centro Fibrosi Cistica di Verona dal 2008 al 2018. Il ruolo implica: il coordinamento dell'attività ambulatoriale (3 ambulatori, 2 infermiere dedicate) e di ricovero (9 letti, 4 medici) dei pazienti adulti; la gestione della lista d'attesa per gli stessi; la collaborazione nella gestione dei pazienti condivisi con i Centri satelliti di Treviso e Rovereto. - Gestione del Servizio di Consulenza Genetica all'interno del Centro Fibrosi Cistica di Verona. Il ruolo implica. la selezione dei casi da consultare; i colloqui di consulenza; i calcoli di rischio residuo; il controllo di fattibilità delle diagnosi prenatali e la loro organizzazione; la gestione del servizio di segreteria per Screening Neonatale e Consulenza Genetica. - Coordinamento del Centro Ricerca Clinica (CRC)) sito all'interno del Centro Fibrosi Cistica (da Giugno 2016). Il ruolo implica: il coordinamento del personale all'interno del CRC (full time: study

	coordinators, statistica, tecnici; part time: infermiere, tecnici spirometria e test sudore; collaboratori esterni); la collaborazione con il Cystic Fibrosis Clinical Trial Network (feasibility studies, riunioni periodiche, partecipazione a studi internazionali proposti); l'arruolamento di pazienti; il ruolo di Principal Investigator nella maggioranza degli studi (fase II e III); la collaborazione con il Centro Ricerche Cliniche sito nella Policlinico (fase I e II); la collaborazione col Laboratorio di Ricerca Traslazionale "Lissandrini" dell'Università di Verona. - Collaborazione ad iniziative di accreditamento: 1) UK Cystic Fibrosis Trust; 2) Accreditamento tra pari a cura di Società Italiana Fibrosi Cistica e Lega Italiana Fibrosi Cistica. Organizzazione dell'application alla rete European Reference Network (ERN), che ha portato il Centro Fibrosi Cistica a essere riconosciuto come membro ERN Lung per le malattie rare.
Capacità e competenze sviluppate in ambito di management e organizzative	Presidente nel 2014-2016 e vicepresidente nel 2011-2013 della Società Italiana Fibrosi Cistica (SIFC). La Società è multidisciplinare e raccoglie tra 200 e 300 iscritti che rappresentano tutti i Centri Fibrosi Cistica Italiani. Organizzatore e coordinatore di tre Consensus Conferences internazionali (1. Analisi genetica nella pratica clinica, 2007; 2. Screening neonatale, 2008; 3. Screening del portatore, 2009). Direttore del progetto internazionale "Standards of Care" per fibrosi cistica, che ha portato alla produzione di nuovi Standard di Cura per la malattia Deputy Editor del "Journal of Cystic Fibrosis" da inizio 2016.
Capacità e competenze sviluppate in ambito di ricerca clinica	Vicedirettore del Clinical Trial Network (CTN) dell'European Cystic Fibrosis negli anni 2011-2013. Il CTN coordina l'attività di ricerca clinica in fibrosi cistica di 43 Centri Fibrosi Cistica in 15 paesi europei e collabora con l'European Medicine Agency (EMA) e la Cystic Fibrosis Foundation (CFF). <u>Studi clinici e progetti di ricerca clinica ultimo decennio e ruolo al loro interno:</u> "Clinical and Functional Translation of CFTR" In collaborazione con Johns Hopkins University, Baltimora European Coordinator: Carlo Castellani "Diagnostic Parameters and Outcomes of CFTR disease in Newborn Screened Infants" In collaborazione con "Genome Canada" Partner: Carlo Castellani "Mapping and Isolation of Genes Influencing Severity of Disease in Cystic Fibrosis" In collaborazione con Toronto Sickkids Hospital. Partner: Carlo Castellani "Prevenire patologie e disabilità congenite attraverso strategie di comunicazione efficaci" Progetto CCM Partner: Carlo Castellani "Cystic fibrosis: to screen or not to screen? Involving citizens' jury in decision on

	carrier screening" Progetto FFC 9/2011 Partner: Carlo Castellani "Task Force on the Provision of Care for Adults with Cystic Fibrosis in Europe" Progetto collaborativo ECFS/ERS Partner: Carlo Castellani "Personalised Characterisation of Rare Cystic Fibrosis Genotypes (CFTR3)" Ruolo: workpackage leader "Citizens' jury and decision making on cystic fibrosis carrier screening: to screen or not to screen?" Progetto FFC 22/2013 Partner: Carlo Castellani "Gene Modifiers and pancreatic phenotype" In collaborazione con Sickkids Hospital Toronto Principal Investigator: Carlo Castellani "Diagnostic parameters and outcomes of CFTR disease in newborn screened infants" Principal Investigator: Carlo Castellani "New strategies for clinical application of noninvasive prenatal diagnosis of cystic fibrosis, based on the analysis of fetal mutated alleles in maternal plasma" Progetto Fondazione Fibrosi Cistica #7/2011 Partner: Carlo Castellani "Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients" In collaborazione con Mukovizidose ev EUDRACT NUMBER: 2011-000801-39 ClinicalTrials.gov Identifier: NCT01455675 Principal Investigator: Carlo Castellani "Uso compassionevole di Kalydeco (ivacaftor) in pazienti affetti da Fibrosi Cistica con mutazione gating NON-G551D" Principal Investigator: Carlo Castellani "Studio multicentrico osservazionale riguardante l'opinione dei pazienti in merito all'assistenza dell'adulto con fibrosi cistica" In collaborazione con SIFC Principal Investigator: Carlo Castellani "Outcomes of spontaneous application of carrier screening for cystic fibrosis: follow-up of its effects on birth prevalence, neonatal screening and reproductive behaviour of carrier couples" Progetto FFC 26/2015 Principal Investigator: Carlo Castellani "Lumacaftor/Ivacaftor Combination Therapy Managed Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation (compassionevole)"

	VX14-809-902 Principal Investigator: Carlo Castellani "A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 g administered once daily via the Respimat device in patients with cystic fibrosis." Boehringer Ingelheim EudraCT No. 2010-019802-17 ClinicalTrials.gov Identifier: SubInvestigator: Carlo Castellani "A Phase 3, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of Lumacaftor monotherapy and in combination with Ivacaftor in subject with Cystic Fibrosis, homozygous for the F508del-CFTR Mutation" Vertex EUDRACT Number: 2012-003989-40 SubInvestigator: Carlo Castellani "A field study in an area of extensive carrier screening for cystic fibrosis" Progetto Fondazione Fibrosi Cistica #8/2011 Principal Investigator: Carlo Castellani "A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (VX-105)" Vertex Eudract Number: 2013-000604-41 ClinicalTrials.gov Identifier: NCT01931839 SubInvestigator: Carlo Castellani "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX-106)" Vertex EudraCT Number: 2014-004837-13 ClinicalTrials.gov Identifier: NCT02347657 Principal Investigator: Carlo Castellani "Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)"Vertex EUDRA CT Number: 2014-002704-24 ClinicalTrials.gov Identifier: NCT02445053 Principal Investigator: Carlo Castellani "A long term prospective observational study of the safety and tolerability of bramitob® administered twice daily over three 28-day "on"/ 28-day "off" cycles to patients with cystic fibrosis having severely compromised lung function" Chiesi Principal Investigator: Carlo Castellani "Long Term Administration of Inhaled Mannitol in Cystic Fibrosis – A Safety and

	Efficacy Trial in Adult Cystic Fibrosis Subjects"Pharmaxis ClinicalTrials.gov Identifier: NCT02134353 Principal Investigator: Carlo Castellani "Observational Registry of Cystic Fibrosis Patients in Europe (VOICE)" Vertex VX14-CFR-107 EUDRACT Number: 2015-002124-76 Principal Investigator: Carlo Castellani "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function (VX-108)" Vertex EudraCT Number: 2014-004788-18 ClinicalTrials.gov Identifier: NCT02392234 Principal Investigator: Carlo Castellani "A Phase 3, Open-Label, Rollover Study to Evaluate the Efficacy and Safety of Long-Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation (VX-110)" Vertex Eudract number: 2014-004827-29 ClinicalTrials.gov Identifier: NCT02565914 Principal Investigator: Carlo Castellani "A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis" Corbus ClinicalTrials.gov Identifier: NCT02465450 Principal Investigator: Carlo Castellani "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis" Celtaxsys ClinicalTrials.gov Identifier: NCT02443688 Principal Investigator: Carlo Castellani "Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients" Bayer EudraCT no.: 2013-004595-35 ClinicalTrials.gov Identifier: NCT02170025 Principal Investigator: Carlo Castellani

Aggiornamenti professionali in ambito di ricerca clinica	19/10/2016 Introduction to Rave EDC, certified by Medidata University Race EDC Essentials for Investigators, certified by Medidata University 5/10/2016 Vertex coding training, certified by Trifecta Multimedia Vertex Non-Protocol Specific Training, certified by Trifecta Multimedia VX-14-661-106 Protocol Specific Training, certified by Trifecta Multimedia VX-14-661-106 EDC Training, certified by Trifecta Multimedia VX-14-CFR-107 PS Training, certified by Trifecta Multimedia 29/9/2016 VX-14-661-106 IB Update Training, certified by Trifecta Multimedia VX-14-CFR-107 NPS Library, certified by Trifecta Multimedia 9/3/2016 InForm GTM 6.0 for Site Users certified by IOL-Oracle
Altri incarichi svolti	Responsabile del progetto "Standards of Care" dell' dell'European Cystic Fibrosis Society Deputy Editor del Journal of Cystic Fibrosis Membro Commissione per la Genetica del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria dal Marzo 1996 al 2000. Responsabile della Commissione per la Genetica del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria dal 29-1-99 al 2000. Consigliere nel Comitato Direttivo del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria (ottobre 1998- novembre 2001) Responsabile della Commissione "Consulenza Genetica in forme atipiche di Fibrosi Cistica" del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria dal 2000 al 2003. Membro dell'European Cystic Fibrosis Diagnostic Network dal giugno 2001 a tutt'oggi Responsabile della "Commissione per il coordinamento di ricerca, diagnostica e consulenza genetica in Fibrosi Cistica e patologie CFTR correlate" del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria dal 2002. Membro del "CF aging international project group" dal 2003. Responsabile della "Commissione di studio sulle modalità di analisi genetica per Fibrosi Cistica" del Gruppo di Studio Italiano per la Fibrosi Cistica della Società Italiana di Pediatria dal 2003. Membro Fondatore dell'European Cystic Fibrosis Society Working Group on Neonatal Screening. Segretario dell'European Cystic Fibrosis Society dal 2006 al 2010. Vicepresidente dell'European Cystic Fibrosis Society dal 2007 al 2010.

	Direttore Scientifico della Fondazione Ricerca Fibrosi Cistica dal 2022
Correlatore a tesi di Laurea	"Indagine sulle informazioni trasmesse in corso di consulenza genetica per fibrosi cistica" Laurea in Medicina e Chirurgia, Università degli studi di Verona, anno accademico 2014-15 "I marcatori di fragilità venosa nei pazienti affetti da fibrosi cistica. Risultati di uno studio osservazionale" Laurea in Infermieristica, Università degli studi di Verona, anno accademico 2015-16
Attività didattica	Scuola di Specializzazione in Pediatria "Genetica delle malattie respiratorie" V° anno per l'a.a. 2003/2004, ore 20 (attribuito ma non svolto) Scuola di specializzazione in Genetica Medica "Genetica clinica prenatale e pediatrica" IV° anno per l'a.a. 2008/2009, ore 6 Scuola Infermieri Professionali di Bussolengo (ULSS 22), insegnamento Pediatria Anno 1988/89 ore 30 Anno 1989/90 ore 30 Anno 1991/92 ore 60 Anno 1992/93 ore 60 Master Università Firenze "Assistenza all'Adulto con Fibrosi Cistica" "Le Mutazioni Del Gene CFTR E Le Prospettive Terapeutiche Attuali e Future" 18 Aprile 2019 "La Diagnosi In Età Adulta: Dalla Genetica Alla Clinica" 10 Giugno 2019 "La Patologia Associata Al Gene CFTR" 7 Ottobre 2019 Docente nella Scuola di Specializzazione in Pediatria dell'Università di Genova anni 2020/21 2021/2022 Responsabile Corso aggiornamento: A tour of Cystic Fibrosis : "Gli strumenti essenziali per avvicinarsi alla fibrosi cistica 2021
Conoscenza di lingue straniere	Inglese scritto e parlato, ottima
Membro di Società Scientifiche	Attuali European Cystic Fibrosis Society European Respiratory Society Società Italiana Fibrosi Cistica Società Italiana di Pediatria Passate American Society of Human Genetics European Society of Human Genetics International Society for Neonatal Screening Società Italiana di Genetica Umana
Premi	2015 European Cystic Fibrosis Society Award, "presented to honour a person who has made an outstanding contribution to our basic understanding of cystic fibrosis or to the treatment or care of patients with cystic fibrosis"
Revisore di articoli scientifici per	- New England Journal of Medicine - The Lancet Respiratory Medicine - American Journal of Respiratory and Critical Care Medicine - Gut

	- Pediatrics - Journal of Cystic Fibrosis - Journal of Paediatrics - Clinical Genetics - American Journal of Medical Genetics - Journal of Paediatric Gastroenterology and Nutrition - Journal of COPD - Prenatal Diagnosis - J Ped Gastr Nutr - Genome Canada - the Netherland Organization for Health Research and Development - Thorax - Journal of Medical Genetics - PLOS ONE - Expert Review of Respiratory Medicine
Metrica pubblicazioni internazionali peer reviewed	h index: 44 (Scopus) citazioni su articoli scientifici: 8489 riviste con pubblicazioni: Lancet Lancet Respir Med Nature Genet JAMA J of Pediatr Pediatrics Gastroenterology Am J Respir Crit Care Med Thorax Eur Resp J J Cyst Fibros Eur J Hum Genet Ped Respir Reviews Arch Dis Child Genet Med Am J Hum Genet Am J Gastroenterol Am J Epidemiol Intern J Clinic Pharmacol Toxicol Pediatric Pulmonology J of asthma Pediatric asthma, allergy and immunology Allergy Hum Genet J Med Genet Acta Paediatr Ann Hum Genet Respiratory medicine Community Genetics J Endocrinol Invest Hum Mutation Pancreatology Genetic Testing Digestive and Liver Disease Am J Med Genet J Mol Med

	Current Opinion in Pulmonary Medicine Clinical and Laboratory Standards Institute Clin Invest Health Expect Semin Respir Crit Care Med PLoS One Rhinology Int J Cardiol Cell Mol Life Sci Int J Mol Sci Int J Antimicrob Agents Int J Neonatal Screen

Pubblicazioni su riviste internazionali (peer reviewed) *in extenso*	1 - Boner AL, Castellani C, Fostini R, Padovani E. Ceftazidime in pediatric infections unsuccessfully treated with other antibiotics: an evaluation of its efficacy and tolerability in compromised host. ***Intern J Clinic Pharmacol Toxicol*** 1986; 6: 333-336. 2 - Boner AL, Bennati D, Castellani C, Sette L, Schiassi M. Bronchodilating activity of oral clenbuterol in asthmatic children after single administration of different dosages. ***Pediatric Pulmonology*** 1987; 3: 34-37. 3 - Boner AL, Sette L, Castellani C. Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma. ***J of asthma*** 1987; 24: 347-353. 4 - Boner AL, Vallone G, De Stefano G, Castellani C, Plebani M. The effect of theophylline on methacoline and exercise-induced bronchoconstriction in asthmatic children. ***Pediatric asthma, allergy and immunology*** 1987; 1: 251-259. 5 - Boner AL, Richelli C, Castellani C, Andreoli A. Comparison of the effects of loratadine and astemizole in the treatment of children with seasonal allergic rhinoconjunctivitis. ***Allergy*** 1992; 47: 98-102. 6 - Bonizzato A, Bisceglia L, Marigo C, Nicolis E, Bombieri C, Castellani C, Borgo G, Zelante L, Mastella G, Cabrini G, Gasparini P, Pignatti PF. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from North-Eastern Italy: identification of 90% of the mutations. ***Hum Genet*** 1995; 95: 397-402. 7 - Castellani C, Bonizzato A, Cazzola GA, Amalfitano G, Mastella G. Burkholderia cepacia and DeltaF508 homozygosity in cystic fibrosis. ***Arch Dis Child*** 1995; 73: 276. 8 - Castellani C, Bonizzato A, Mastella G. CFTR mutations and IVS8-5T variant in newborns with hypertrypsinemia and normal sweat test. ***J Med Genet*** 1997; 34: 297-301. 9 - Castellani C, Bonizzato A, Cabrini G, Mastella G. Newborn screening strategy for cystic fibrosis: a field study in an area with high allelic heterogeneity. ***Acta Paediatr*** 1997; 86: 497-502. 10 -Rendine S, Calafell F, Cappello N, ..., Castellani C, ..., Piazza A. Genetic history of cystic fibrosis mutations in Italy: I regional distribution. ***Ann Hum Genet*** 1997; 61: 411-424.

11– Pradal U, Castellani C, Delmarco A, Mastella G. Nasal Potential Difference in Congenital Bilateral Absence of the Vas Deferens. ***Am J Respir Crit Care Med*** 1998; 158: 896-901.

12 - Castellani C, Benetazzo MG, Bonizzato A, Pignatti PF, Mastella G. Cystic Fibrosis Mutations in Heterozygous Newborns with Hypertrypsinemia and Low Sweat Chloride. ***Am J Hum Genet***, 1999; 64: 303-304.

13 - Castellani C, Bonizzato A, Rolfini R, Frulloni L, Cavallini GC, Mastella G. Increased prevalence of mutations of the cystic fibrosis gene in idiopathic chronic and recurrent pancreatitis. ***Am J Gastroenterol***, 1999; 94: 1993-1994.

14- Castellani C, Bonizzato A, Pradal U et al. Evidence of mild respiratory disease in men with Congenital Absence of the Vas Deferens. ***Respiratory medicine***, 1999; 93: 869-875.

15 - Borgo G, Castellani C, Bonizzato A, Rolfini R, Altieri S, Zanolla L, Mastella G. Carrier testing program in a high risk cystic fibrosis population fron North-eastern Italy. ***Community Genetics***, 1999; 2: 82-90.

16 - Castellani C, Tamanini A, Mastella G. Protracted neonatal hypertrypsinogenaemia , normal sweat chloride and cystic fibrosis. ***Arch Dis Child***, 2000; 82: 481-2.

17 - Gomez Lira M, Benetazzo MG, Marzari MG, Bombieri C, Belpinati F, Castellani C, Cavallini GC, Mastella G, Pignatti PF. High frequency of cystic fibrosis transmembrane regulator mutation L997F in patients with recurrent idiopathic pancreatitis and in newborns with hypertrypsinemia. ***Am J Hum Genet***, 2000; 66: 2013-14.

18 - Quinzii C, Castellani C. The cystic fibrosis transmembrane regulator gene and male infertility. ***J Endocrinol Invest***, 2000; 23: 684-689.

19 - Castellani C, Benetazzo MG, Tamanini A, Begnini A, Mastella G, Pignatti PF. Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in neonatal hypertrypsinemia with normal sweat test. ***J Med Genet***, 2001; 38:202-205.

20 - Castellani C, Gomez Lira M, Frulloni L, Delmarco A, Marzari M, Bonizzato A, Cavallini G, Pignatti PF, Mastella G. Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in idiopathic pancreatitis. ***Hum Mutation***. 2001;18:166.

21 - Mastella G, Zanolla L, Castellani C, Altieri S, Furnari M, Giglio L, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. ***Pancreatology*** 2001; 1: 531-537.

22 - Gomez Lira M, Patuzzo C, Castellani C, Bovo P, Cavallini G, Mastella G, Pignatti PF. CFTR and cationic trypsinogen mutations in idiopathic pancreatitis and in neonatal hypertrypsinemia. ***Pancreatology*** 2001; 1: 538-542.

23 - Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. ***Genetic Testing*** 2001; 5: 249-54.

24 - Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG.

Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. ***Am J Epidemiol*** 2002; 156: 397-401.

25 - Patuzzo C, Castellani C, Sagramoso C, Gomez-Lira M, Bonamini D, Belpinati F, et al. Cationic trypsinogen and pancreatic secretory trypsin inhibitor gene mutations in neonatal hypertrypsinemia. ***Eur J Hum Genet*** 2003; 11: 93-96.

26 - Frulloni L, Castellani C, Bovo P, Vaona B, Calore B, Liani C, Mastella G, Cavallini G. Natural history of pancreatitis associated with cystic fibrosis gene mutations. ***Digestive and Liver Disease*** 2003; 35: 179-185.

27 - Castellani C. Evidence for newborn screening for cystic fibrosis. ***Ped Respir Reviews***, 2003; 4:278-284.

28 - Gomez-Lira M, Bonamini D, Castellani C, Cavallini G, Unis L, Assael BM, Pignatti PF. Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients. ***Eur J Hum Genet*** 2003; 11: 543-546.

29 - Decaestecker K, Decaestecker E, Castellani C, Jaspers M, Cuppens H, De Boeck K. Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients. ***Eur Resp J*** 2004 23: 679-684.

30 - Castellani C, Picci L, Scarpa M, Dechecchi MC, Zanolla L, Assael BM, Zacchello F. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers. ***Am J Med Genet*** 2005 135A: 141-144.

31 - Bombieri C, Bonizzato A, Castellani C, Assael BM, Pignatti PF. Frequency of large CFTR gene rearrangements in Italian CF patients. ***Eur J Hum Genet*** 2005 13: 687-689.

32 - De Boeck K, Wilschanski M, Castellani C, Taylor CJ, Cuppens H, Dodge JA, Sinaasappel M. Cystic fibrosis: terminology and diagnostic algorithms. ***Thorax*** 2006; 61:627-35.

33 - Ferec C, Casals T, Chuzhanova N, Macek M Jr, Barton D, Castellani C, et al. Gross genomic rearrangements involving deletions in the CFTR gene: characterization of six new events from a large cohort of hitherto unidentified cystic fibrosis chromosomes and meta-analysis of their underlying mechanisms. ***Eur J Hum Genet*** 2006 May;14(5):567-76

34 - Witt H, Sahin-Toth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani C, Cavestro GM, Cerny M, Destro-Bisol G, Spedini G, Eiberg H, Jansen JB, Koudova M, Rausova E, Macek M Jr, Malats N, Real FX, Menzel HJ, Moral P, Galavotti R, Pignatti PF, Rickards O, Spicak J, Zarnescu NO, Bock W, Gress TM, Friess H, Ockenga J, Schmidt H, Pfutzer R, Lohr M, Simon P, Weiss FU, Lerch MM, Teich N, Keim V, Berg T, Wiedenmann B, Luck W, Groneberg DA, Becker M, Keil T, Kage A, Bernardova J, Braun M, Guldner C, Halangk J, Rosendahl J, Witt U, Treiber M, Nickel R, Ferec C. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. ***Nat Genet***. 2006 Jun;38(6):668-673.

35 - Castellani C, Malerba G, Sangalli A, Delmarco A, Petrelli E, Rossini M, Assael BM, Mottes M. The genetic background of osteoporosis in cystic fibrosis: Association analysis with polymorphic markers in four candidate genes. ***J Cyst Fibros*** 2006 May 16; 5: 229-235.

36 - Ciminelli BM, Bonizzato A, Bombieri C, Pompei F, Gabaldo M, Ciccacci C, Bagnini A, Holubova A, Zorzi P, Piskackova T, Macek M Jr, Castellani C, Modiano G, Pignatti PF. Highly preferential association of NonF508del CF mutations with the M470 allele. ***J Cyst Fibros***. 2007; 6: 15-22.

37 - Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C; on behalf of the ECFS CF Neonatal Screening Working Group. A survey of newborn screening for cystic fibrosis in Europe. ***J Cyst Fibros***. 2007 Jan;6(1):57-65

38 - Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, Gruca M, Tamanini A, Assael MB, Gaskin K. Pancreatic phenotype in cystic fibrosis patients identified by mutation screening. ***Arch Dis Child***. 2007; 92: 842-846.

39 - Treiber M, Schulz HU, Landt O, Drenth JP, Castellani C, Real FX, Akar N, Ammann RW, Bargetzi M, Bhatia E, Demaine AG, Battagia C, Kingsnorth A, O'reilly D, Truninger K, Koudova M, Spicak J, Cerny M, Menzel HJ, Moral P, Pignatti PF, Romanelli MG, Rickards O, De Stefano GF, Zarnescu NO, Choudhuri G, Sikora SS, Jansen JB, Weiss FU, Pietschmann M, Teich N, Gress TM, Ockenga J, Schmidt H, Kage A, Halangk J, Rosendahl J, Groneberg DA, Nickel R, Witt H. Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. ***J Mol Med***. 2006 Dec;84(12):1015-22.

40 - Picci L, Cameran M, Scarpa M, Pradal U, Melotti P, Assael BM, Castellani C. TG15 T5 allele in clinically discordant monozygotic twins with cystic fibrosis. Am ***J Med Genet*** A. 2007 Aug 15;143(16):1936-7

41 - Scotet V, Assael BM, Duguépéroux I, Tamanini A, Audrézet MP, Férec C, Castellani C. Time trends in birth incidence of cystic fibrosis in two European regions: data from newborn screening programmes. ***J of Pediatr*** 2008; 152: 25-32.

42 – Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. ***J Cyst Fibros***. 2008;7(3):179-96.

43 - Mayell SJ, Munck A, Craig JV, Sermet I, Brownlee KG, Schwarz MJ, Castellani C, Southern KW; On behalf of the European Cystic Fibrosis Society Neonatal Screening Working Group. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. ***J Cyst Fibros***. 2009; 8:71-8.

44 - Hodson ME, Simmonds NJ, Warwick WJ, Tullis E, Castellani C, Assael B, Dodge JA, Corey M, For The International Study Of Aging In Cystic Fibrosis. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. ***J Cyst Fibros***. 2008; 7:537-42.

45 - Dequeker E, Stuhrmann M, Morris MA, Casals T, Castellani C, Claustres M, Cuppens H, Georges MD, Ferec C, Macek M, Pignatti PF, Scheffer H, Schwartz M, Witt M, Schwarz M, Girodon E. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders - updated European recommendations. ***Eur J Hum Genet***. 2009; 17:51-65.

46 - Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR,

Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. ***J Pediatr***. 2008 Aug;153(2):S4-S14.

47 - Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, Mehta A, Munck A, Pollitt R, Sermet-Gaudelus I, Wilcken B, Ballmann M, Corbetta C, deMonestrol I, Farrell P, Feilcke M, Férec C, Gartner S, Gaskin K, Hammermann J, Kashirskaya N, Loeber G, Macek M Jr, Mehta G, Reiman A, Rizzotti P, Sammon A, Sands D, Smyth A, Sommerburg O, Torresani T, Travert G, Vernooij A, Elborn S. European best practice guidelines for cystic fibrosis neonatal screening. ***J Cyst Fibros***. 2009; 8:153-73.

48 - Azad AK, Rauh R, Vermeulen F, Jaspers M, Korbmacher J, Boissier B, Bassinet L, Fichou Y, Georges MD, Stanke F, De Boeck K, Dupont L, Balaščáková M, Hjelte L, Lebecque P, Radojkovic D, Castellani C, Schwartz M, Stuhrmann M, Schwarz M, Skalicka V, de Monestrol I, Girodon E, Férec C, Claustres M, Tümmler B, Cassiman JJ, Korbmacher C, Cuppens H. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. ***Hum Mutat***. 2009; 30:1093-103.

49. Perobelli S, Zanolla L, Tamanini A, Rizzotti P, Maurice Assael B, Castellani C. Inconclusive Cystic Fibrosis neonatal screening results: long-term psychosocial effects on parents. ***Acta Paediatr***. 2009; 98: 1927-34.

50. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. ***JAMA*** 2009; 302:1076-83.

51. Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. ***JAMA*** 2009; 302:2573-9.

52.Castellani C, Macek M Jr, Cassiman JJ, Duff A, Massie J, Ten Kate LP, Barton D, Cutting G, Dallapiccola B, Dequeker E, Girodon E, Grody W, Highsmith EW, Kääriäinen H, Kruip S, Morris M, Pignatti PF, Pypops U, Schwarz M, Soller M, Stuhrman M, Cuppens H. Benchmarks for Cystic Fibrosis carrier screening: A European consensus document. ***J Cyst Fibros***. 2010 : 9 : 165-178.

53.Castellani C, Massie J. Emerging Issues in Cystic Fibrosis Newborn Screening. ***Current Opinion in Pulmonary Medicine*** 2010: 16: 584-590.

54.Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J, Berthiaume Y, Corey M, Schibli S, Tullis E, Durie PR. Type of CFTR Mutation Determines Risk of Pancreatitis in Patients With Cystic Fibrosis. ***Gastroenterology***. 2011; 140: 153-161.

55.Castellani C, Perobelli S, Bianchi V, Seia M, Melotti P, Zanolla L, Assael BM, Lalatta F. An interactive computer program can effectively educate potential users of cystic fibrosis carrier tests. ***Am J Med Genet*** 2011 Apr;155A(4):778-85

56. Bombieri C, Claustres M, de Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C,

Cuppens H, Cutting GR, Dřevínek P, Durie P, Farrell P, Gonska T, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek Jr M, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern K, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C. Recommendations for the classification of diseases as cftr-related disorders. ***J Cyst Fibr***, 2011 Jun;10 Suppl 2:S86-102.

57. Farrell P, Boas SR, Castellani C, et al. Clinical and Laboratory Standards Institute – Newborn screening for cystic fibrosis: approved guideline. CLSI document NBS05- A. Wayne. PA: ***Clinical and Laboratory Standards Institute***; 2011.

58. Bulteel V, Castellani C, Conway SP, Dubois C, Fajac I, Pereira L, Reimann ALG, s De Boeck K. Developing an international network for clinical research: the European Cystic Fibrosis Society – Clinical Trials Network experience. ***Clin. Invest***. (2011) 1(6), 775–780

59 Castellani C; CFTR2 team. CFTR2: How will it help care? ***Paediatr Respir Rev***. 2013 May;14 Suppl 1:2-5.

60 Sorio C, Angiari C, Johansson J, Verzè G, Ettorre M, Buffelli M, Castellani C, Assael BM, Melotti P. Impaired CFTR function in mild cystic fibrosis associated with the S977F/T5TG12 complex allele in trans with F508del mutation. ***J Cyst Fibros***. 2013 Dec;12(6):821-5.

61 Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR. Defining the disease-liability of mutations in the cystic fibrosis transmembrane conductance regulator gene. ***Nature Genetics***, 2013 Oct;45(10):1160-7.

62 Massie J, Castellani C, Grody WW. Carrier Screening for Cystic Fibrosis in the New Era of Medications that Restore CFTR Function. ***Lancet***, 2013 Mar 8;383(9920):923-5.

63 Castellani C, Massie J. Newborn screening and carrier screening for cystic fibrosis: alternative or complementary? ***Eur Respir J*** 2014 Jan;43(1):20-3..

64 Fajac I, Bulteel V, Castellani C et al. The European Cystic Fibrosis Society–Clinical Trials Network: an international network to optimize clinical research for a rare disease. ***Clin. Invest***. 3(10), 921–926 (2013).

65 Thomas M, Lemonnier L, Gulmans V, Naehrlich L, Vermeulen F, Cuppens H, Castellani C, Norek A, De Boeck K. Is there evidence for correct diagnosis in cystic fibrosis registries? ***J Cyst Fibros***. 2014 May;13(3):275-80..

66 Castellani C, Conway S, Smyth AR, Stern M, Elborn JS. Standards of Care for Cystic Fibrosis ten years later. ***J Cyst Fibros***. 2014 May;13 Suppl 1:S1-2.

67 Stern M, Bertrand DP, Bignamini E, Corey M, Dembski B, Goss CH, Pressler T, Rault G, Viviani L, Elborn JS, Castellani C. European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. ***J Cyst Fibros***. 2014 May;13 Suppl 1:S43-59.

68 De Boeck K, Castellani C, Elborn JS; ECFS Board. Medical consensus, guidelines, and position papers: a policy for the ECFS. ***J Cyst Fibros***. 2014 Sep;13(5):495-8.

69 Mosconi P, Castellani C, Villani W, Satolli R. Cystic fibrosis: to screen or not to screen? Involving a Citizens' jury in decisions on screening carrier. ***Health Expect***. 2015 Dec;18(6):1956-67

70 Terlizzi V, Carnovale V, Castaldo G, Castellani C, Cirilli N, Colombo C, Cresta F, Lucarelli M, Lucidi V, Macchiaroli A, Madarena E, Padoan R, Quattrucci S, Salvatore D, Raia V. Clinical expression of patients with Cystic Fibrosis and D1152H mutations. ***J Cyst Fibros*** 2015 Jul;14(4):447-52.

71 Ooi C, Castellani C, Keenan K, Avolio J, Volpi S, Boland M, Kovesi T, Bjornson C, Chilvers MA, Morgan L, van Wylick R, Kent S, Price A, Solomon M, Tam K, Taylor L, Ann-Malitt K, Ratjen F, Durie P, Gonska T. Inconclusive diagnosis for cystic fibrosis after newborn screening. ***Pediatrics*** 2015 Jun;135(6):e1377-85.

72 Braido f, Baiardini I, Sumberesi M, Canonica GW, Blasi F, Castellani C. Public awareness on Cystic Fibrosis: results from a national pragmatic survey. ***Eur Resp J***, 2015 Jul;46(1):264-7.

73 Bombieri C, Seia M, Castellani C. Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders. ***Semin Respir Crit Care Med***. 2015 Apr;36(2):180-93.

74 D'Ambrosio A, Agricola E, Russo L, Gesualdo F, Pandolfi E, Bortolus R, Castellani C, Lalatta F, Mastroiacovo P, Tozzi AE. Web-based surveillance of public information needs for informing preconception interventions. ***PLoS One***. 2015 Apr 16;10(4):e0122551. doi: 10.1371/journal.pone.0122551.

75 Castellani C, Picci L, Tridello G, Casati E, Tamanini A, Bartoloni L, Scarpa M, Assael BM. Cystic fibrosis carrier screening effects on birth prevalence and newborn screening. ***Genet Med***. 2016 Feb;18(2):145-51.

76 Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, Gonska T. Prevalence of meconium ileus marks the severity of mutations of the Cystic FibrosisTransmembrane Conductance Regulator (CFTR) gene. ***Genet Med***. 2016 Apr;18(4):333-40.

77 Baldan A, Lo Presti AR, Belpinati F, Castellani C, Bettin MD, Xumerle L, Pignatti PR, Malerba G, Bombieri C. IFRD1 gene polymorphisms are associated with nasal polyposis in cystic fibrosis patients. ***Rhinology***. 2015 Dec;53(4):359-64

78 Scarsini R, Prioli MA, Milano EG, Castellani C, Pesarini G, Assael BM, Vassanelli C, Ribichini FL. Hemodynamic predictors of long term survival in end stage cystic fibrosis. ***Int J Cardiol***. 2015 Sep 12;202:221-225.

79 Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. ***Eur Respir J***. 2016 Feb;47(2):420-8.

80 Sosnay PR, Castellani C, Penland CM, Rommens JM, Lewis M, Raraigh KS, Corey M, Cutting GR. Bias in CFTR screening panels. ***Genet Med***. 2016 Feb;18(2):209.

81 Castellani C, Massie J, Sontag M, Southern KW. Newborn screening for cystic

fibrosis. ***Lancet Respir Med***. 2016 Aug;4(8):653-61

82 Galbiati S, Monguzzi A, Damin F, Soriani N, Passiu M, Castellani C, Natacci F, Curcio C, Seia M, Lalatta F, Chiari M, Ferrari M, Cremonesi L. COLD-PCR and microarray: two independent highly sensitive approaches allowing the identification of fetal paternally inherited mutations in maternal plasma. ***J Med Genet***. 2016 Jul;53(7):481-7

83 Castellani C, Tridello G, Tamanini A, Assael BM. Sweat chloride and immunoreactive trypsinogen in infants carrying two CFTR mutations and not affected by cystic fibrosis. ***Arch Dis Child***. 2016 Jan 11. pii: archdischild-2015-309348. doi: 10.1136/archdischild-2015-309348.

84 Castellani C, Assael BM. Cystic fibrosis: a clinical view. ***Cell Mol Life Sci***. 2016 Oct 5. PMID: 27709245

85. Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, Linnane B, Mayell S, Munck A, Sands D, Sommerburg O, Pybus S, Winters V, Southern KW. The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe. **J Cyst Fibros**. 2017 Mar;16(2):207-213.

86. Bortolus R, Oprandi NC, Rech Morassutti F, Marchetto L, Filippini F, Agricola E, Tozzi AE, Castellani C, Lalatta F, Rusticali B, Mastroiacovo P. Why women do not ask for information on preconception health? A qualitative study. **BMC Pregnancy Childbirth**. 2017 Jan 5;17(1):5

87. Farrell PM, White TB, Derichs N, Castellani C, Rosenstein BJ. Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. **J Pediatr**. 2017 Feb;181S:S16-S26.

88. Sosnay PR, Salinas DB, White TB, Ren CL, Farrell PM, Raraigh KS, Girodon E, Castellani C. Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses. **J Pediatr.** 2017 Feb;181S:S27-S32

89 Bell SC, Castellani C, Flume PA. Learning's from the Editors Desk - 2017. ***J Cyst Fibros***. 2017 Nov;16(6):645-646

90 Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. ***J Cyst Fibros***. 2018 Mar;17(2):153-178.

91 Mosconi P, Colombo C, Roberto A, Candiani G, Greco MT, Satolli R, Castellani C. Deciding on cystic fibrosis carrier screening: three citizens' juries and an online survey. ***Eur J Public Health***. 2018 Mar 19. doi: 10.1093/eurpub/cky032. [Epub ahead of print]

92 Tridello G, Castellani C, Meneghelli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ***ERJ Open Res.*** 2018 Apr 20;4(2)

93 Gramegna A, Aliberti S, Seia M, Porcaro L, Bianchi V, Castellani C, Melotti P, Sorio C, Consalvo E, Franceschi E, Amati F, Contarini M, Gaffuri M, Roncoroni L, Vigone B, Bellofiore A, Del Monaco C, Oriano M, Terranova L, Patria MF, Marchisio P, Assael BM and Blasi F. When and how ruling out cystic fibrosis in

adult patients with bronchiectasis. ***Multidisciplinary Respiratory Medicine*** 2018, 13(Suppl 1):29, 21-7.

94 Keenan K, Dupuis A, Griffin K, Castellani C, Tullis E, Gonska T. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His. ***J Cyst Fibros***. J Cyst Fibros. 2019 Mar;18(2):265-270. doi: 10.1016/j.jcf.2018.09.002.

95 Castellani C, Boner AL. Aquagenic wrinkling and cystic fibrosis carriership: a dubious relationship. ***European Journal of Internal Medicine***. Eur J Intern Med. 2018 Nov;57:e43. doi: 10.1016/j.ejim.2018.09.007.

96 **Castellani C**, Linnane B, Pranke I, Cresta F, Sermet-Gaudelus I, Peckham D. Cystic Fibrosis Diagnosis in Newborns, Children, and Adults. Semin Respir Crit Care Med. 2019 Nov 3. doi: 10.1055/s-0039-1697961.

97 Ooi CY, Sutherland R, **Castellani C**, Keenan K, Boland M, Reisman J, Bjornson C, Chilvers MA, van Wylick R, Kent S, Price A, Mateos-Corral D, Hughes D, Solomon M, Zuberbuhler P, Brusky J, Durie PR, Ratjen F, Gonska T. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis. BMC Pediatr. 2019 Oct 22;19(1):369. doi: 10.1186/s12887-019-1756-4.

98 Saffioti C, Barco S, Cangemi G, Mesini A, Casciaro R, Cresta F, **Castellani C**, Bandettini R, Morelli P, Castagnola E. Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for *Bulkholderia cepacia* reacutization. J Chemother. 2019 Oct 4:1-3. doi: 10.1080/1120009X.2019.1671654.

99 Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, **Castellani C**, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020 Jan;8(1):65-124.

100 Salvatore D, Carnovale V, Iacotucci P, Braggion C, **Castellani C**, Cimino G, Colangelo C, Francalanci M, Leonetti G, Lucidi V, Manca A, Vitullo P, Ferrara N. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations. *Pediatr Pulmonol.* 2019 Sep;54(9):1398-1403. doi: 10.1002/ppul.24424.

101 Southern KW, Barben J, Gartner S, Munck A, **Castellani C**, Mayell SJ, Davies JC, Winters V, Murphy J, Salinas D, McColley SA, Ren CL, Farrell PM. Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition. *J Cyst Fibros*. 2019 Apr 24. pii: S1569-1993(19)30070-0. doi: 10.1016/j.jcf.2019.04.010.

102 McCague AF, Raraigh KS, Pellicore MJ, Davis-Marcisak EF, Evans TA, Han ST, Lu Z, Joynt AT, Sharma N, **Castellani C**, Collaco JM, Corey M, Lewis MH, Penland CM, Rommens JM, Stephenson AL, Sosnay PR, Cutting GR. Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis. *Am J Respir Crit Care Med.* 2019 May 1;199(9):1116-1126. doi: 10.1164/rccm.201901-0145OC.

103 Bell SC, **Castellani C**, Flume PA. JCF - progress in 2018. *J Cyst Fibros*. 2019 Jan;18(1):1-5. doi: 10.1016/j.jcf.2018.12.008.

104. Bell SC, **Castellani C**, Flume PA. Disruption in research publishing - the open access revolution. *J Cyst Fibros*. 2019 Nov;18(6):747-749.

105. Delatycki MB, Alkuraya F, Archibald A, **Castellani C**, Cornel M, Grody WW, Henneman L, Ioannides AS, Kirk E, Laing N, Lucassen A, Massie J, Schuurmans J, Thong MK, van Langen I, Zlotogora J. International perspectives on the implementation of reproductive carrier screening. *Prenat Diagn*. 2019 Nov 27. doi: 10.1002/pd.5611

106. **Castellani C**. Conclusion and Prospects: Genetics of cystic fibrosis - an agenda for the next ten years. *Arch Pediatr*. 2020 Feb;27 Suppl 1:eS45-eS47

107. Bell SC, Flume PA, **Castellani C**. Seven P's of publication practices. *J Cyst Fibros*. 2020 Feb 21:S1569-1993(20)30053-9. doi: 10.1016/j.jcf.2020.02.007.

108. **Castellani C** Healthcare Reassessment In A Pandemics Time: Challenges For CF. *J Cyst Fibros*. 2020 Mar;19(2):194-195. doi: 0.1016/j.jcf.2020.03.010.PMID: 32527496

109. Cresta F, Arcuri L, Bianchin S, **Castellani C**, Casciaro R, Cavedagna TM, Maghnie M, Barco S, Cangemi A case of interference in testosterone, DHEA-S and progesterone measurements by second generation immunoassays G.Clin Chem Lab Med. 2021 Feb 1. doi: 10.1515/cclm-2020-1786.

110. Flume PA, **Castellani C**, Davies J. JCF Year in Review. J Cyst Fibros. 2021 Jan;20(1):1-2. doi: 10.1016/j.jcf.2021.01.004.PMID: 33526211

111. Ciprandi R, Bonati M, Campi R, Pescini R, **Castellani C**. Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown. J Cyst Fibros. 2020 Dec 23:S1569-1993(20)30948-6. doi: 10.1016/j.jcf.2020.12.016.

112. Barben J, **Castellani C**, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, McColley S, Ooi CY, Proesmans M, Ren CL, Salinas D, Sands D, Sermet-Gaudelus I, Sommerburg O, Southern KW; European CF Society Neonatal Screening Working Group (ECFS NSWG). Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros. 2020 Nov 27:S1569-1993(20)30909-7. doi: 10.1016/j.jcf.2020.11.006.

113. **Castellani C**. Newborn Screening for Cystic Fibrosis: Over the Hump, Still Need to Fine-Tune It. Int J Neonatal Screen. 2020 Jul 9;6(3):57. doi: 10.3390/ijns6030057.

114. Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, **Castellani C**. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci. 2020 Aug 16;21(16):5882. doi: 10.3390/ijms21165882.PMID: 32824306

115. Amerio A, Sibilla F, Pescini R, Ciprandi R, Casciaro R, Grimaldi Filioli P, Porcelli C, Odone A, Costanza A, Aguglia A, Serafini G, Amore M, **Castellani C**,

Cresta F. Mental health and cystic fibrosis: Time to move from secondary prevention to predictive medicine. Pediatr Pulmonol. 2020 Sep;55(9):2204-2206. doi: 10.1002/ppul.24928. Epub 2020 Jul 7.PMID: 32634297

116. Flume P, **Castellani C**. JCF Year in Review. J Cyst Fibros. 2020 Jul;19(4):505-506. doi: 10.1016/j.jcf.2020.06.007.PMID: 32593371

117. Pedrazzi M, Vercellone S, Barberis E, Capraro M, De Tullio R, Cresta F, Casciaro R, **Castellani C**, Patrone M, Marengo E, Lecca P, Melotti P, Sorio C, Manfredi M, Averna M. Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis. Int J Mol Sci. 2021 Apr 10;22(8):3928. doi: 10.3390/ijms22083928

118. Olcese C, Casciaro R, Pirlo D, Debbia C, Castagnola E, Cresta F, **Castellani C**. SARS-CoV-2 and Burkholderia cenocepacia infection in a patient with Cystic Fibrosis: An unfavourable conjunction? J Cyst Fibros. 2021 May;20(3):e29-e31. doi: 10.1016/j.jcf.2021.03.024.

119. Cresta F, Arcuri L, Bianchin S, **Castellani C**, Casciaro R, Cavedagna TM, Maghnie M, Barco S, Cangemi G. A case of interference in testosterone, DHEA-S and progesterone measurements by second generation immunoassays. Clin Chem Lab Med. 2021 Feb 1;59(7):e275-e277. doi: 10.1515/cclm-2020-1786.

120. Munck A, Southern KW, **Castellani C**, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, Proesmans M, Sands D, Sommerburg O, Barben J; European CF Society Neonatal Screening Working Group (ECFS NSWG). Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis. J Cyst Fibros. 2021 Sep;20(5):820-823. doi: 10.1016/j.jcf.2021.02.006

121. Borgo C, D'Amore C, Capurro V, Tomati V, Sondo E, Cresta F, **Castellani C**, Pedemonte N, Salvi M. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants. Cell Mol Life Sci. 2022 Mar 16;79(4):192. doi: 10.1007/s00018-022-04215-3.

122. Castagnola E, Cangemi G, Mesini A, **Castellani C**, Martelli A, Cattaneo D, Mattioli F. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. Int J Antimicrob Agents. 2021 Sep;58(3):106381. doi: 10.1016/j.ijantimicag.2021.106381. Epub 2021 Jun 19.

123. Sondo E, Cresta F, Pastorino C, Tomati V, Capurro V, Pesce E, Lena M, Iacomino M, Baffico AM, Coviello D, Bandiera T, Zara F, Galietta LJV, Bocciardi R, **Castellani C**, Pedemonte N. The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. Int J Mol Sci. 2022 Mar 15;23(6):3175. doi: 10.3390/ijms23063175.

124. Simmonds NJ, van der Ent CK, Colombo C, Kinnman N, DeSouza C, Thorat T, Chew ML, Chandarana K, **Castellani C**. VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations. J Cyst Fibros. 2022 May 22:S1569-1993(22)00141-2. doi: 10.1016/j.jcf.2022.05.007.

125. Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N, Majo F, Ciciriello F, Padoan R,

Poli P, Taccetti G, Centrone C, Casciaro R, **Castellani C**, Salvatore D, Colangelo C, Bonomi P, Castaldo G, Terlizzi V. Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. J Cyst Fibros. 2022 Sep;21(5):850-855. doi: 10.1016/j.jcf.2022.04.020. Epub 2022 May 4.

126. Raraigh KS, Lewis MH, Collaco JM, Corey M, Penland CM, Stephenson AL, Rommens JM, **Castellani C**, Cutting GR. Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants. J Cyst Fibros. 2022 Sep;21(5):856-860. doi: 10.1016/j.jcf.2022.04.019.

127. **Castellani C**, De Boeck K, De Wachter E, Sermet-Gaudelus I, Simmonds NJ, Southern KW; ECFS Diagnostic Network Working Group. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. J Cyst Fibros. 2022 Oct 8:S1569-1993(22)00691-9. doi: 10.1016/j.jcf.2022.09.011. Online ahead of print.

128. Munck A, Berger DO, Southern KW, Carducci C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Proesmans M, Sands D, Sommerburg O, **Castellani C**, Barben J; European CF Society Neonatal Screening Working Group (ECFS NSWG). European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance. J Cyst Fibros. 2022 Nov 10:S1569-1993(22)00689-0. doi: 10.1016/j.jcf.2022.09.012.

129. Tomati V, Costa S, Capurro V, Pesce E, Pastorino C, Lena M, Sondo E, Di Duca M, Cresta F, Cristadoro S, Zara F, Galietta LJV, Bocciardi R, **Castellani C**, Lucanto MC, Pedemonte N. Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background. J Cyst Fibros. 2022 Dec 19:S1569-1993(22)01425-4. doi: 10.1016/j.jcf.2022.12.005.

130. Kevin W. Southern,**Carlo Castellani**,Elise Lammertyn,...Marieke Verkleij, Michael D. Waller, Alistair Duff Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. JCF Published online: October 27, 2022

131. Tosco A, Carnovale V, Claut L, Fabrizzi B, Majo F, **Castellani C**, Sepe A, Castaldo G, Terlizzi V. Clinical outcome of individuals carrying 5T;TG12 in trans with CFTR variants with varying clinical consequences. Pediatr Pulmonol. 2023 Jan 17. doi: 10.1002/ppul.26323.

132. Pigliasco F, Cafaro A, Stella M, Baiardi G, Barco S, Pedemonte N, D'Orsi C, Cresta F, Casciaro R, **Castellani C**, Calevo MG, Mattioli F, Cangemi G. Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients' Plasma by a Novel LC-MS/MS Method. Biomedicines. 2023 Feb 20;11(2):628. doi: 10.3390/biomedicines11020628

133. **Castellani C**. When triple therapy is not working: A reverse iceberg perspective. J Cyst Fibros. 2023 Mar 5:S1569-1993(23)00063-2. doi: 10.1016/j.jcf.2023.02.012.

134. Terlizzi V, Pesce E, Capurro V, Tomati V, Lena M, Pastorino C, Bocciardi R, Zara F, Centrone C, Taccetti G, **Castellani C**, Pedemonte N. Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators. Int J Mol Sci. 2023 Mar 31;24(7):6576. doi: 10.3390/ijms24076576.

135. Amerio A, Magnani L, **Castellani C**, Schiavetti I, Sapia G, Sibilla F, Pescini R, Casciaro R, Cresta F, Escelsior A, Costanza A, Aguglia A, Serafini G, Amore

M, Ciprandi R. The Expression of Affective Temperaments in Cystic Fibrosis Patients: Psychopathological Associations and Possible Neurobiological Mechanisms. Brain Sci. 2023 Apr 5;13(4):619. doi: 10.3390/brainsci13040619.

136. Southern KW, Burgel PR, **Castellani C**, De Boeck K, Davies JC, Dunlevy F, Fajac I, Gramegna A, Lammertyn E, Middleton PG, Ratjen F, van Koningsbruggen-Rietschel S. Standards for the care of people with cystic fibrosis (CF). J Cyst Fibros. 2023

137. **Castellani C**, Simmonds NJ, Barben J, Addy C, Bevan A, Burgel PR, Drevinek P, Gartner S, Gramegna A, Lammertyn E, Landau EEC, Middleton PG, Plant BJ, Smyth AR, van Koningsbruggen-Rietschel S, Girodon E, Kashirskaya N, Munck A, Nährlich L, Raraigh K, Sermet-Gaudelus I, Sommerburg O, Southern KW. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis. J Cyst Fibros. 2023

138. Capraro M, Pedrazzi M, De Tullio R, Manfredi M, Cresta F, **Castellani C**, Averna M. Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators. Int J Mol Sci. 2023

139. Strati MF, Bassi M, Pescini R, Ciprandi R, Cresta F, d'Annunzio G, **Castellani C**, Minuto N, Casciaro R. Mixed educational camps for children and adolescents with type 1 diabetes and cystic fibrosis: A new therapeutic alliance. Pediatr Pulmonol. 2023

140. Terlizzi V, Padoan R, Amato A, Campagna G, **Castellani C**, Salvatore M. Hidden CFSPID in CF patient registries? The Italian CF Registry experience. J Cyst Fibros. 2023

141. De Wachter E, Davies JC, Simmonds NJ, **Castellani C**, de Winter-de Groot KM, Munck A, Proesmans M, Southern KW, Barben J. Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI. J Cyst Fibros. 2023

142. Banzi R, Allocati E, Gerardi C, **Castellani C**, Rissone M, Stracuzzi M, Ferrario L, Foglia E, Mosconi P, Colombo C. Effectiveness of preconceptional and prenatal cystic fibrosis carrier screening: a systematic review. Epidemiol Prev. 2023 Jul-Oct;47(4-5):243-256.

143. Andrea Gramegna, Stefano Aliberti, Adelina Amorim, Francesco Blasi, Stephen Bourke, Pierre-Régis Burgel, Filia Diamantea, Isabelle Durieu, Libor Fila, Rosa María Girón Moreno, Barbara Messore, Eva Pokojová, Giovanni Taccetti, Stijn Verhulst, Andrea Vukić Dugac, Sabine Wege, Alistair Duff, Kevin W. Southern, **Carlo Castellani**. Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis. J Cyst Fibros Available online 8 November 2023

144. Anne Munck, Kevin W. Southern, Jared Murphy, Karin M. de Winter-de Groot, Silvia Gartner, Bülent Karadag, Nataliya Kashirskaya, Barry Linnane, Marijke Proesmans, Dorota Sands, Olaf Sommerburg, **Carlo Castellani** and Jürg Barben on behalf of the European CF Society Neonatal Screening Working Group (ECFS NSWG). Cystic Fibrosis Cases Missed by Newborn Bloodspot Screening—Towards a Consistent Definition and Data Acquisition. Int. J. Neonatal Screen. 2023, 9, 65. https://doi.org/10.3390/ijns9040065

145. Burgel PR, Southern KW, Addy C, Battezzati A, Berry C, Bouchara JP, Brokaar E, Brown W, Azevedo P, Durieu I, Ekkelenkamp M, Finlayson F, Forton

	J, Gardecki J, Hodkova P, Hong G, Lowdon J, Madge S, Martin C, McKone E, Munck A, Ooi CY, Perrem L, Piper A, Prayle A, Ratjen F, Rosenfeld M, Sanders DB, Schwarz C, Taccetti G, Wainwright C, West NE, Wilschanski M, Bevan A, **Castellani C**, Drevinek P, Gartner S, Gramegna A, Lammertyn E, Landau EEC, Plant BJ, Smyth AR, van Koningsbruggen-Rietschel S, Middleton PG. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros. 2024 Jan 16:S1569-1993(24)00005-5. 146. Southern K, Addy C, Bell S, Bevan A, Borawska U, Brown C, Burgel PR, Button B, **Castellani C**, Chansard A, Chilvers M, Davies G, Davies J, De Boeck K, Declercq D, Doumit M, Drevinek P, Fajac I, Gartner S, Georgiopoulos A, Gursli S, Gramegna A, Hansen CM, Hug M, Lammertyn E, Landau EEC, Langley R, Mayer-Hamblett N, Middleton A, Middleton P, Mielus M, Morrison L, Munck A, Plant B, Ploeger M, Bertrand DP, Pressler T, Quon BS, Radtke T, Saynor ZL, Shufer I, Smyth AR, Smith C, West NE, van Koningsbruggen-Rietschel S. Standards for the care of people with cystic fibrosis; establishing and maintaining health. J Cyst Fibros. 2023 Dec 20:S1569-1993(23)01727-7
Pubblicazioni su riviste nazionali	Castellani C, Boner AL. Asma e ritmi circadiani. *Riv Ital Ped* 1985; 11: 793-798. Vallone G, Castellani C, Sette L, Boner AL. Studio comparativo della broncoostruzione indotta dalla corsa libera e dalla provocazione con metacolina somministrata mediante dosimetro Mefar. *La clinica pediatrica* 1985; 67: 557-565. Castellani C, Boner AL. Il bambino asmatico e la sua famiglia: le prospettive nell'educazione sanitaria e nella gestione della malattia. *Acta Paed Latina* 1986; 39: 147-155. Castellani C, Sette L, Andreoli A, Boner AL. Beta-2 agonisti per via orale: confronto tra clenbuterolo e procaterolo. *Acta Ped Latina* 1987; 40: 750-756. Boner AL, Vallone G, Bennati D, Castellani C. Reazioni tardive isolate dopo broncoprovocazione specifica con Dermatophagoides pteronyssinus in bambini con asma bronchiale cronica. *Riv. Ital. Ped.* 1987; 13: 379-383. Boner AL, Castellani C. High altitude specialized center for asthmatic children: an Italian experience in Misurina. *Acta Ped Latina* 1987; 40: 742-749. Andreoli A, Castellani C. Emosiderosi polmonare nell'infanzia: forma idiopatica. *Acta Paed. Latina* 1987; 40: 158-167. Andreoli A, Castellani C. Emosiderosi polmonare nell'infanzia : associazione con altre patologie. *Acta Paed Latina* 1987; 40:168-184. Castellani C, Boner AL. Proporzioni e margini di prevenzione di un fenomeno trascurato: la morte per asma. *Giornale italiano delle malattie del torace* 1988; 42: 103-109. Antognoni G, Armenio L, Baldini G, ….., Castellani C, et al. La prevenzione dell'asma infantile attraverso l'educazione sanitaria. Risultati ottenuti in Italia con corsi educativi sull'asma infantile. *Riv It Broncopneum Ped* 1988; 1: 3-45. Piacentini GL, Peroni DG, Castellani C, Boner AL. Farmaci antiallergici : III. Antistaminici classici e di nuova sintesi nelle malattie alergiche in età pediatrica. *Acta Paed. Latina* 1989; 42: 535-546.

Boner AL, Andreoli A, Valletta EA, Castellani C. Modalità alternative di somministrazione dell'immunoterapia specifica. *Riv. Ital. Ped.* 1989; 15: 1-5.

Boner AL, Castellani C, De Stefano G. Le malattie allergiche del bambino. *Quaderni dell'Ulss 25*, Verona, 1989.

1Boner AL, Castellani C, Piacentini G. Terapia dell'asma nel primo anno di vita. *Riv Broncopneum Ped* 1989; 1: 62-70.

Bonizzato C, Sette L, Castellani C, Boner AL. Gestione dell'asma del bambino (I): Problemi in fase diagnostica. *Acta Ped Latina* 1990; 43: 315-32.

Castellani C, Sette L, Comis A, Benedetti M, Boner AL. Il salbutamolo a rilascio controllato nell'asma infantile: farmacocinetica, efficacia terapeutica, tollerabilità. *Acta Paed. Latina* 1991; 44: 76-85.

Castellani C, Benedetti M, Spezia E, Comis A, Sette L, Boner AL. Influenza della terapia con beta2-agonisti sulla reattività bronchiale. *Acta Paed. Latina* 1991; 44: 67-75.

Castellani C, Baronio G, Boner AL. La terapia non farmacologica dell'asma. Norme igieniche e comportamentali. *Asma allergia immunopatologia* 1991; 82: 9-18.

Boner AL, Piacentini G, Castellani C. Nuovi farmaci antiallergici. *Prospettive in pediatria* 1991; 21: 73-78.

Castellani C, Boner AL. Diagnosi di asma. *Gaslini* 1992; 24: 14-17.

Benedetti M, Degani D, Battisti L, Borgna Pignatti C, Castellani C, Boner AL. Sindrome polmonare ostruttivo-restrittiva insorta dopo trapianto di midollo osseo per talassemia. Descrizione di un caso clinico e revisione della letteratura. *Riv Ital Pediatr* 1992; 18: 472-477.

Boner AL, Piacentini GL, Castellani C. Prevenzione dell'asma e dell'allergia mediante provvedimenti ambientali. *Riv Pediatr Prev Soc* 1992; 42: 119-121.

Castellani C., Piovesan P. Il parmigiano reggiano nella dieta del bambino sano e malato. *Acta Paed Latina* 1993; 46: 129-131.

Castellani C, Del Col G, Boner AL. Basi epidemiologiche: morbilità e mortalità dell'asma. *Acta Paed Latina* 1993; 46: 117-128.

Castellani C, Gamba MC. Diarree acute infantili: osservazioni epidemiologiche, eziologiche e cliniche, in una casistica ospedaliera (1988-1991). *Il Fracastoro* 1994; 87: 87-94.

Castellani C. Screening del portatore di tratti genetici recessivi: è già tempo di scelte? Il caso della fibrosi cistica. *Prospettive in Pediatria*, 1996; 26: 275-28.

Castellani C. Aree critiche di diagnosi di fibrosi cistica e loro implicazioni prognostiche e di consulenza genetica: infertilità maschile, pancreatite cronica ed acuta ricorrente, diagnosi incerta da screening neonatale. *Riv Ital Pediatr* 1998; 24 (suppl al n. 2): 78-81.

Borgo G, Cantù-Rainoldi A, Castellani C, et al. Sullo screening della fibrosi cistica. *Quaderni ACP* 1998; 6: 35.

	Campagnola S, Fasoli L, Flessati P, Sulpasso M, Castellani C. Vas deferens anomalies in paediatric age. *Minerva Pediatr* 1999; 51: 265-9. Castellani C. Dieci anni dalla scoperta del gene della fibrosi cistica: implicazioni cliniche. *Aggiornamenti di fisiopatologia e terapia in pediatria*, 2000; 10: 14-21. Borgo G, Lalatta F, Cantù-Raynoldi A, Castellani C, Ferrari M, Giunta AM, Iapichino L, Lucci M, Scarpa M. Linee guida per l'uso del test genetico per fibrosi cistica. *Aggiornamenti di Fisiopatologia e terapia in Pediatria* vol 11, 5-17. Castellani C. Extensive genetic analysis for neonatal screening. Proceedings of 25th European CF Conference Genoa June 20-23 2002. Editors Romano L, Manno G, Galietta LJV Castellani C, Lalatta L, Neri D, Novelli G, Piccinini A, Seia M, Toricelli F. Modelli di analisi genetica per fibrosi cistica. Programma Nazionale Linee Guida 1, Dicembre 2005. Castellani C. Fibrosi cistica atipica. *Medico e Bambino* 2006 163-168. Bonizzato A, Castellani C. La diagnostica molecolare della fibrosi cistica e delle malattie correlate a mutazioni del gene CFTR. *Biochimica clinica* 2008; 32: 77-84. Castellani C, Seia M. Fibrosi cistica: analisi preconfezionale e prenatale. *Rivista Italiana Medicina di Laboratorio.* 2010; 6: 89-96. Intervista a Carlo Castellani. La fibrosi cistica, lo screening neonatale e lo screening del portatore. *Medico e Bambino* 2011; XXX 3: 180-182. Elisabetta Bignamini, Federico Cresta, Barbara Messore, Irene Esposito, Antonella Lezo, Sara De Michelis, Elena Nave, Carlo Castellani. CFTRpatie. *Pneumologia Pediatrica*. 2019; 73:33-41.
Capitoli di libri	Boner AL, Castellani C, Peroni D, Piacentini GL. Controllo ambientale e prevenzione farmacologica. Dal volume "*Allergologia pediatrica*" Il pensiero scientifico editore 1989; 181-196. Patrick R. Sosnay, Carlo Castellani, Mary Corey, Ruslan Dorfman, Julian Zielenski, Rachel Karchin, Christopher M. Penland, and Garry R. Cutting. Evaluation of the Disease Liability of CFTR Variants. From: M.D. Amaral, K. Kunzelmann (eds.), *Cystic Fibrosis*, Methods in Molecular Biology 742, DOI 10.1007/978-1-61779-120-8_21, © Springer Science+Business Media, LLC 2011 Castellani C, Assael BM. Trastornos relationados con CFTR. From: *Tratado de Fibrosis Quistica*. Edited by Sociedad Espanola Fibrosis Quistica, Sociedad de Neumologia Pediatrica, Sociedad Espanola de Gastroenterologia, Epatologia y Nutricion Pediatrica Munck A, Bui S, Oteri S, Castellani C. The impact of newborn bloodspot screening on the diagnosis and well-being of pre-school children with CF. From: *The early cystic fibrosis years*, Editors Kris De Boeck and Kevin Southern, ECFS, June 2018, pages 14-25. Castellani C, Simmonds N. 'Identifying undiagnosed cystic fibrosis in adults with bronchiectasis' accepted for publication in the ERS Monograph edition: 81: Bronchiectasis.

	Sian Betley, Daniel Peckham, Carlo Castellani, Nicola Shaw. Cystic fibrosis medication: present and future. From: Optimizing pharmaceutical care in cystic fibrosis. Editors: Sian Betley, Carlo Castellani, Daniel Peckham, Nicola Shaw. From: European Cystic Fibrosis Society, December 2020 Carlo Castellani Portatori di fibrosi cistica: informare per scegliere con consapevolezza. Quaderni ACP Anno. 2023, Volume. 30, N. 4, Pag. 164-165 Banzi R, Allocati E, Gerardi C, Castellani C, Rissone M, Stracuzzi M, Ferrario L, Foglia E, Mosconi P, Colombo C. Efficacia dello screening preconcezionale del portatore di fibrosi cistica: revisione sistematica. Epidemiol Prev. 2023 Jul-Oct;47(4-5):243-256.
Editoria di libri	Healthcare issues and challenges in adolescents with cystic fibrosis. Editors: Carlo Castellani, Stuart Elborn, Harry Heijerman. From: European Cystic Fibrosis Society, December 2012 Milestones in fibrosi cistica. Editor: Carlo Castellani. Oxys publishing 2016 Gli adulti con fibrosi cistica – White Book. Editors: Carlo Castellani, Domenico Tangolo. SIFC 2016. Optimizing pharmaceutical care in cystic fibrosis. Editors: Sian Betley, Carlo Castellani, Daniel Peckham, Nicola Shaw. From: European Cystic Fibrosis Society, December 2020
Organizzazione di meeting scientifici	- "Forme atipiche di fibrosi cistica: un network per la diagnosi ed il follow-up". Evento accreditato ECM. Verona 24/02/2006 - "Use and interpretation of cystic fibrosis mutation analysis in the clinical setting" International Consensus Conference of the European Cystic Fibrosis Society, European Society of Human Genetics and EuroGentest. Hotel Poiano, Garda 23-24/03/2007 - - "European best practice guidelines for cystic fibrosis neonatal screening", International Consensus Conference of the European Cystic Fibrosis Society, EuroCareCF, and the International Neonatal Screening Society. Hotel Poiano, Garda 28-29/03/08 - "Benchmarks for Cystic Fibrosis Carrier Screening", International Consensus Conference of the European Cystic Fibrosis Society, European Society of Human Genetics and EuroGentest. Hotel Poiano, Garda 20-21/03/09 - "Adult care in cystic fibrosis. Assistenza al paziente adulto con fibrosi cistica: l'esperienza di un centro adulti europeo" Verona 6/3/2010 - "Cystic Fibrosis Diagnostic Network Meeting" Verona March 2012 - "Cystic Fibrosis Standards of Care Consensus Conference" Verona March 12-13 2013.
Partecipazione a Board Scientifici	- Scientific Committee 25th European Cystic Fibrosis Conference (Genoa) - Organising Committee 5th International Society for Neonatal Screening

	- Scientific Committee 26th European Cystic Fibrosis Conference (Belfast) - Cystic Fibrosis Genetic Testing and Screening, European Cystic Fibrosis Network (Leuven) - Abbott Cystic Fibrosis advisory board (Birmingham) - Scientific Committee 27th European Cystic Fibrosis Conference (Birmingham) - Scientific Committee 28th European Cystic Fibrosis Conference (Crete) - Scientific Committee 29th European Cystic Fibrosis Conference (Copenhagen) - Clinical and Laboratory Standard Institute Subcommittee on Newborn Screening for Cystic Fibrosis - Scientific Committee 41st European Cystic Fibrosis Conference (Belgrade) - Scientific Committee 42nd European Cystic Fibrosis Conference (Liverpool)
Relazioni in conferenze internazionali (invited speaker)	Higher prevalence of Pseudomonas cepacia colonization among delta F508 Homozygotes in a group of italian CF patients. 19° European Cystic Fibrosis Conference, ***Paris*** 29 May – 3 June 1994. CFTR mutations and IVS8-5T prevalence in idiopathic chronic and recurrent pancreatitis. 11° North American Cystic Fibrosis Conference, ***Nashville*** 23-26 October 1997. The problem of newborns with hypertrypsinemia, CFTR heterozygosity and normal sweat test. 5° International Conference on Neonatal Screenig for Cystic Fibrosis, ***Caen*** 10-11 September 1998. Additional CFTR mutations in heterozygous newborns with hypertrypsinemia and negative sweat test. 12° Annual North American Cystic Fibrosis Conference, ***Montreal*** 15-18 October 1998. Heterozygote detection in neonatal cystic fibrosis screening. 4°th Meeting of the International Society for Neonatal Screening., ***Stockholm***, 13-16 June 1999. Acute mid abdominal pain. 14th North American Cystic Fibrosis Conference, November 9-12, 2000, ***Baltimore***, USA Heterozygotes identified through CF neonatal screening. 24th European Cystic Fibrosis Conference, 6-9 June 2001, ***Vienna***, Austria. Diagnostic of CF: European perspective. In Symposium "Diagnostic criteria for Cf and non-CF disorders". 15° North American Cystic Fibrosis Conference, ***Orlando*** 25-28 October 2001. Extensive genetic analysis for neonatal screening, Workshop "Neonatal screening" 25th European Cystic Fibrosis Conference, 20-23 June 2002, ***Genoa***. A survey on cystic fibrosis neonatal screening practice around Europe. 28th European Cystic Fibrosis Conference, ***Crete***, 22-25 June 2005. A survey on cystic fibrosis neonatal screening practice around Europe. 4th

	European meeting of the International Society for Neonatal Screening, ***Paris*** 5-6 September 2005. "Incidence of cystic fibrosis in Europe: data from CF neonatal screening programmes" 29th European CF Conference ***Copenhagen*** 15-18 June 2006 An interactive educational software for decision-making in cystic fibrosis genetic testing. EuroGentest General Assemby 11-13 December 2006 ***Leuven***, Belgium Conclusions from the 2007 Garda Conference on CFTR Genetics. Cystic Fibrosis Foundation Meeting on "Diagnostic Criteria for Cystic Fibrosis in a new Era of early recognition through Newborn Screening" May 7-8 2007 ***Bethesda*** USA The European Experience 30th European Cystic Fibrosis Conference, 13-16 June 2007, ***Belek***, Turkey How to make the diagnosis: the easy one, the difficult one. European Respiratory Society Conference, 15-19/09/2007 ***Stockholm*** Use and interpretation of cystic fibrosis mutation analysis in the clinical setting: a consensus report. 21st North American Cystic Fibrosis Conference ***Anaheim*** 3-6 October 2007-10-09 Genetic testing and Neonatal Screening in CF in Europe. 1st regional Meeting on CF, ***Zagreb*** 16-17 October 2007 Dépistage national et état de lieux en Europe. Journées annuelles de la Mucoviscidose, ***Paris*** 6-7 Decembre 2007 Cystic Fibrosis Newborn Screening activities in Europe. Newborns Screening Issues and Answers series: Cystic Fibrosis ***Bethesda***, hosted by National Newborn Screening and Genetics Resource Center USA January 16 2008 "Challenges ahead". Consensus Conference "Cystic Fibrosis Neonatal Screening in Europe: Development, Management, Research" ***Garda*** 28-29 March 2008. "Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report" CF Diagnostic Network Meeting ***Prague*** 11 June 2008. "Consensus on use and Interpretation of mutation analysis in the clinical setting" 31st European Cystic Fibrosis Conference ***Prague*** 11-14 June 2008. "CFTR related disorders" 2nd EuroCareCF workshop on CFTR related diseases ***Prague*** 15-16 June 2008. "CFTR mutation analysis in the clinical setting" "Reunion Internacional de Neumologia Pediatrica" ***Mexico City*** 8-12 September 2008. "Extensive carrier testing and CF birth prevalence: evidence for a negative correlation"" 32nd European Cystic Fibrosis Conference ***Brest*** 10-13 June 2008. "Activity and consensus of the ECFS Cystic Fibrosis Neonatal Screening Working Group", 6th European Regional Meeting in Neonatal Screening, ***Prague*** 26-28 April 2009. "Performance of an Italian CF Neonatal Screening Program over a 16 Year

	Period", 23rd North American Cystic Fibrosis Conference, ***Minneapolis*** 15-17 October 2009. "Cystic fibrosis newborn screening in Europe: what is happening and why, including current barriers to implementation" Meeting "Progress and challenges in cystic fibrosis newborn screening: perspectives from the USA, Europe and Spain" ***Valencia*** 16 June 2010. "How do we define cystic fibrosis?" National Cystic Fibrosis Meeting, ***Cardiff***, UK September 24th 2010. "Diagnostic Sweat testing" European Respiratory Society ***online course*** "The management of infants identified with cystic fibrosis following newborn screening"October 26th 2010. "Drug allergy in cystic fibrosis" Convegno "Verona allergy and respiratory forum – Drug allergy and drugs for allergy" ***Verona*** October 29th 2010. "CTN expansion". Clinical Trail Network Steering Committee Meeting, ***Paris*** 13-14/01/2011 "Newborn screening in CF: the next challenge" Meeting: Frontiers in Exocrine Pancreas Disease; ***Toronto*** May 13th 2011 "CTN expansion: selection process and outcome". Clinical Trail Network Steering Committee Meeting, ***Hamburg*** 8/6/2011 "Progress in CF newborn screening: towards a more efficient detection system" VIII Congreso Latino Americano de errores innatos del metabolismo y pesquisa neonatal. ***Cuzco*** (Perù) 18-21/09/2011. "CFTR2 Genotype/Phenotype; Its Relevance to European databases" 35th European Cystic Fibrosis Conference, ***Dublin*** 6-9 June 2012 "CF mutations in Europe implications for therapy" Cystic fibrosis European Masterclass 2013 - delivering quality care in cystic fibrosis ***Parma*** March 16 2012 "CFTR II" The 26th symposium: Cystic fibrosis in adults and children organised by Paediatrics & Child Health Section, organised by the Royal Society of Medicine ***London*** November 20th 2012 "Genotype and phenotype of CF and CFTR disorders" British Thoracic Society Winter Meeting 2012; ***London*** Wednesday 5 to Friday 7 December 2012 "CFTR2: Update and future plans"ECFS Diagnostic Network Working Group Meeting ***Jerusalem***, February 14-15th 2013 "Diagnosis of CF and related disorders in the newborn infant" 36th European CF Conference, ***Lisbon***, Portugal, 12-15 June 2013 "Screening for CF in Europe: are we improving?" European Respiratory Society annual congress, ***Barcelona***, 7-11 September 2013. "CFTR2 Genetics, Functional Analysis & Implication for Future Therapies" 27th Annual North American Cystic Fibrosis Conference, ***Salt Lake City*** October 17-19 2013

	"Understanding mutations" Cystic fibrosis European Masterclass 2013 - delivering quality care in cystic fibrosis ***Prague*** April 5 2013 "Carrier screening and Neonatal screening for cystic fibrosis: a complex relationship" European Society of Human Genetics Conference, ***Milan*** May 31 - June 3 2014. "The new ECFS standards of care: Why and how" 37th European CF Conference, ***Gothenburg***, Sweden, 11-14 June 2014 "How to get the most out of the CFTR-2 resource" 37th European CF Conference, ***Gothenburg***, Sweden, 11-14 June 2014 "Carrier screening and incidence trends in cystic fibrosis" 1st International Workshop on Large scale population-based surveys on respiratory health in Italy and Europe, ***Verona*** October 23/24 2014 "Assessment of the disease liability of CFTR mutation" LEAD in Cystic Fibrosis, Lectures, Education, Awareness and Discussion. ***Prague*** December 4-5/2014. "CFTR2, Compound heterozygotes and sweat test" ECFS Diagnostic Network meeting, ***Warsaw*** 12-14 February 2015. "Carrier screening and genotype/phenotype correlation" VI annual North-Western international research-to-practice conference on cystic fibrosis "Genetics, Diagnostics, Complications, Rehabilitation" ***Saint-Petersburg*** 15-16th May 2015 "CFTR2 and mutation oriented therapies" VI annual North-Western international research-to-practice conference on cystic fibrosis "Genetics, Diagnostics, Complications, Rehabilitation" ***Saint-Petersburg*** 15-16th May 2015 "The ECFS standards of care" VI annual North-Western international research-to-practice conference on cystic fibrosis "Genetics, Diagnostics, Complications, Rehabilitation" ***Saint-Petersburg*** 15-16th May 2015 "2015 ECFS award: in varietate concordia" 38th European Cystic Fibrosis Conference ***Brussels*** 10-13 June 2015 "Exploring barriers to implementation of screening for CF" 38th European Cystic Fibrosis Conference ***Brussels*** 10-13 June 2015 "Difficult diagnosis of CF: CFTR-RD" ERS school ***Prague*** 19-21 November 2015 "Carrier screening and newborn screening: friends or foes?" LEAD ***Barcelona*** 22 April 2016 "Long Term Benefits of Newborn Screening in CF: Lessons Learned" CIPP XV / Fifteenth International Congress on Pediatric Pulmonology / ***Naples***, June 23-26, 2016 "All bronchiectasis patients have cystic fibrosis, until proven otherwise?" 2nd World Bronchiectasis Conference ***Milan*** July 6 to July 8 2017 "Cystic fibrosis: how to manage adults in Italy " European Respiratory Society Conference ***Milan*** September 9th 2017

	"The role of genotyping in CFTR2" 18th National Cystic Fibrosis Clinical Meeting ***Killarney*** 1-2 February 2018 "ECFS standards of care" ERN LUNG annual meeting, ***Frankfurt*** March 7-8 2018 "NGS and the understanding of disease-causing versus neutral alleles: the cystic fibrosis paradigm" Clinical Genomics and NGS, ***Bertinoro*** April 29 – May 4 2018 "CFTR-RD: is this adult CFSPID?" 41st European Cystic Fibrosis Conference ***Belgrade*** 6-9 June 2018 "European Standards of Care How did we make and maintain them?" MECFC 2019 Towards Optimal CF Care in the Middle East. ***Istanbul***, March 20-22 2019 "CRMS/CFSPID" MECFC 2019 Towards Optimal CF Care in the Middle East. ***Istanbul***, March 20-22 2019 "Avances en el tratamiento de Fibrosis Quística: nuevas alternativas basadas en mutaciones" SLEIMPN XI ***Buenos Aires*** 2019 "CFTR-related disorders: still relevant in 2019?" 42nd ECFS Conference ***Liverpool***, United Kingdom, 5-8 June 2019 "CFSPID in infants: false positive or late onset?" Neonatal screening for cystic fibrosis in Europe and in US for today, tomorrow and beyond. ***Brest***, February 6° 2019 "(Re)discovering mucoactive drugs in CF" 1st Adult Cystic Fibrosis International Workshop, ***Milan***, 5-6 September 2019 "CFTR mutations: what they can and what they can't tell us" North American Cystic Fibrosis Conference ***Nashville*** USA 31 October – 2 November 2019. "The CFTR related disorders project: introductory recommendations and work". 45th ECFS Conference, 8-11 June 2020, **Rotterdam** "CFTR related disorders guidelines: guideline overview and key highlights" North American Cystic Fibrosis Conference November 2022 **Philadelphia**
Relazioni in conferenze nazionali	Il ceftazidime in infezioni pediatriche risultate resistenti ad altri antibiotici. Convegno nazionale di antibioticoterapia in età pediatrica Milano, 8 novembre 1985. Patologie infettive emergenti in gastroenterologia. Convegno "Ecografia ed infettivologia pediatrica" Lazise 1989. Cutireazione e iperreattività bronchiale, indagata mediante gasthmatic, in 146 bambini con e senza asma. Convegno "Età e sistema respiratorio" Verona 1990. Autogestione delle malattie allergiche. Convegno: "Le malattie allergiche del bambino" Verona 3 febbraio 1990. Esperienza pediatrica di vaccinazioni in soggetti a rischio nell'Ulss 26. Convegno: " La vaccinazione di massa contro l'epatite B: attualità e prospettive; Garda 23 novembre 1991.

	Lo screening neonatale della fibrosi cistica: l'esperienza di 22 anni nel Triveneto e nuovo programma. Convegno "Screening genetico della fibrosi cistica", Verona 13 maggio 1995. Tavola rotonda: Carrier testing e carrier screening: tempo di decidere per domani. 4° Congresso Nazionale Fibrosi Cistica, Milano, 15-16 marzo 1996. ICSI e rischi di trasmissione della fibrosi cistica. Convegno: Sterilità maschile: trattamento con la intracytoplasmatic sperm injection. Bologna 21 dicembre 1996. L'approccio diagnostico per la fibrosi cistica nel maschio infertile. Convegno: Infertilità maschile: nuovi orientamenti diagnostici.. Padova 28 febbraio 1998. Aree critiche di diagnosi di fibrosi cistica e loro implicazioni prognostiche e di consulenza genetica: infertilità maschile, pancreatite cronica ed acuta ricorrente, diagnosi incerta da screening neonatale. 6° Congresso Nazionale Fibrosi Cistica, Roma 16-18 Aprile 1998. Un approccio alternativo: l'esperienza della Regione Veneto. 3° Congresso Nazionale della Società Italiana per gli Screening Neonatali. Giornata dedicata a: "Linee guida per lo Screening Neonatale per la Fibrosi Cistica. Milano 24 Ottobre 1998. Attività della Commissione Genetica del Gruppo Italiano Fibrosi Cistica: presentazione di linee guida per l'utilizzo del test genetico e consensi informati all'analisi genetica ed alla diagnosi prenatale. Convegno del Gruppo Italiano Fibrosi Cistica, Positano, Dicembre 1999. Mutazioni CFTR e pancreatite idiopatica. Convegno: Aggiornamento di patologia pancreatica e dintorni. Verona, 24-25 febbraio 2000. Documenti sulla diagnosi genetica. VII Congresso nazionale del Gruppo Italiano di Studio sulla Fibrosi Cistica della Società Italiana di Pediatria. Cosenza 3-5 Dicembre 2000 Analisi del gene CFTR in pazienti con pancreatite. Convegno: Attualità in tema di diagnostica della Fibrosi Cistica. Milano 15-16 Dicembre 2000. Genetica molecolare: 10 anni di esperienza nel Centro Fibrosi Cistica di Verona. Convegno: La diagnosi prenatale: aspetti organizzativi, Verona 26-01-2002. Genotipo vs fenotipo: a che punto siamo. Convegno: le molte facce della fibrosi cistica: confronto tra specialisti. Trieste 9-10 settembre 2005. "Dalle forme classiche alle forme atipiche" Convegno "Cosa di nuovo insegna il gene della fibrosi cistica", Monza 29 ottobre 2005. Screening Neonatale in Europa: protocolli e progetti. II congresso nazionale Società Italiana Fibrosi Cistica. Firenze 23-25 novembre 2006. La consulenza genetica e riproduttiva. II congresso nazionale Società Italiana Fibrosi Cistica. Firenze 23-25 novembre 2006. Il significato clinico del test genetico per fibrosi cistica. VI Corso di Aggiornamento in Genetica Clinica, Genova 28/03/2007

	Il significato clinico dell'indagine genetica nella fibrosi cistica. Convegno "Biologia molecolare della fibrosi cistica ed evoluzione del test genetico: dai kit mutazionali standard all'analisi delle macrodelezioni" 23/05/2007 Milano "Cosa succede in Italia e nel mondo". Convegno "Lo screening della fibrosi cistica: dobbiamo riparlarne". Trieste 30 Gennaio 2008-11-08 "Proposte internazionali per l'implementazione dei programmi di screening neonatale della fibrosi cistica" "Congresso Nazionale Congiunto SISMME SISN SIMGePeD Palermo 28-30 Ottobre 2008. "Genetica ed Epidemiologia della Fibrosi Cistica" Convegno "Fibrosi Cistica: modello di rete assistenziale in Veneto" Treviso 7 Novembre 2008. "Cystic Fibrosis and CFTR related diseases" IV Congresso Nazionale Società Italiana Fibrosi Cistica Torino 27-29 Novembre 2008. "Stato dell'arte sul progetto CFTR2", V Congresso Nazionale Società Italiana Fibrosi Cistica Soverato 1-4 Ottobre 2009. "Carrier screening: linee guida europee", V Congresso Nazionale Società Italiana Fibrosi Cistica Soverato 1-4 Ottobre 2009. "Screening del portatore di fibrosi cistica e indagini prenatali". Convegno "Lo screening dal preconcezionale all'età evolutiva" Comano (Tn) 7-8 maggio 2010. "Fibrosi Cistica: analisi precooncezionale e prenatale" Convegno "Patologia Clinica della gravidanza" Altavilla Vicentina (VI) 27-28 maggio 2010. "Screening per la fibrosi cistica prima dei trattamenti di procreazione medicalmente assistita?" Convegno "Procreazione medicalmente assistita: percorsi" Creazzo (Vi) 22 ottobre 2010. "Drug allergy in cystic fibrosis" Convegno "Verona allergy and respiratory forum – Drug allergy and drugs for allergy" Verona October 29th 2010. "Il porgetto CFTR1 e il progetto CFTR2" Master "Assistenza e ricerca per la fibrosi cistica: dal neonato all'adolescente e al giovane adulto" Firenze 11 Novembre 2010. "Come è cambiata l'epidemiologia della fibrosi cistica: il paziente adulto" XVI Congresso Italiano della Fibrosi Cistica Rimini 18-21 Novembre 2010. "Fibrosi cistica: come cambia l'epidemiologia nel Veneto. Dati veneti e internazionali" Convegno "Fibrosi cistica: recenti progressi in epidemiologia e clinica" Treviso 11-12 Marzo 2011 "Il Pediatra deve ancora pensare alla diagnosi di Fibrosi Cistica di fronte ad uno screening neonatale negativo?"67° Congresso Nazionale SIP, Milan June 7-10 2011 ""Vecchie" malattie "nuove" acquisizioni: Fibrosi Cistica" Corso di Genetica Medica; Roma 23-24 giugno 2011 "La Fibrosi Cistica in Italia: presentazione della Società Italiana Fibrosi Cistica" – Incontro Novartis Basilea 8-10 settembre 2011

	"Protocolli e Linee Guida per lo Screening della Fibrosi Cistica" Congresso Nazionale Congiunto SIMMESN e SIMGePeD; Bologna 27-29 ottobre 2011 "Linee Guida CLSI per lo Screening Neonatale" VII Congresso Italiano SIFC - Tirrenia 23-26 Novembre 2011 "Scenari dopo CFTR2" Meeting Concern Fibrosi Cistica Milano 27-28 settembre 2013 "Fibrosi Cistica" XLII Congresso Nazionale AIPO Verona, 27-30 novembre 2013 "Clinicians meet investigators: Genetics and screening" X Convention d'Autunno dei Ricercatori in Fibrosi Cistica. Verona, November 29 – December 1, 2012 "Cos'è la fibrosi cistica: numeri, volumi, statistiche" Convegno "Screening neonatale in Fibrosi Cistica...e in Puglia?" Bari 19 December 2013 "Le raccomandazioniERS/ECFS" Un respiro profondo XII Forum internazionale Milan, 3-4 March 2014 "Task Force Europea e linee-guida nel paziente adulto" Cystic Fibrosis Open Day. Presente e futuro: una sfida per il sistema sanitario. Rome May 24 2014. "Standard of care in fibrosi cistica: presente e futuro" Up to date su nutrizione e ventilazione non invasiva in fibrosi cistica. Ancona, 7/8 November 2014 "Nuovi farmaci: prevenzione o terapia?" II° Forum italiano sulla fibrosi cistica; Fiuggi, 22-23 November 2014. "Fibrosi cistica: l'evoluzione della patologia" 9° Forum Risk Management in Sanità, Arezzo 25 November 2014. "I nuovi standard di cura europei" XII Forum Internazionale Pneumologia, Milan 9-10 March 2015. "Il modello fibrosi cistica" Pharmacogenetics and Global Health: strenghtening a global rare diseases system. Verona April 17 2015 "Fibrosi cistica: la terapia genica" Scuola Medica Ospedaliera, Azienda Ospedaliera Universitaria Integrata; La ricerca respiratoria oggi per la cura delle malattie polmonari domani. Verona 29 Ottobre 2015 "May appropriate locations and appropriate biomarkers allow for personalized medicine? Can they direct the decision to a specific clinical treatment? The reasons why we need them." Biomarkers to personalize treatment of the basic defect and to monitor early response. 13th Convention of FFC investigators in CF. 26-28 novembre 2015. Garda (Verona) "Cosa la genetica ci ha insegnato per la fibrosi cistica: dalle forme atipiche alla terapia" Seminari Congiunti Specializzazione Di Genetica Medica - Hugef - Dottorato Di Scienze Biomediche E Oncologia, Curriculum Di Genetica Umana. Torino 9 febbraio 2016 "Carrier screening ed epidemiologia della fibrosi cistica che cambia" XIV Forum di Pneumologia Obiettivo respiro e respiro obiettivo Milano 7-8 Marzo 2016

	"Fibrosi cistica: un paradigma di nuove opportunità e di paradossi nelle malattie genetiche" Accademia di Agricoltura Scienze e Lettere di Verona «I Giovedì della scienza» Verona 17 marzo 2016 "Screening del portatore e neonatale, strumenti di diagnosi e prevenzione" Focus Sulla Fibrosi Cistica 1991 – 2016 E Oltre "Sogni In Corso" Matera 9 aprile 2016 "Medicina di precisione in fibrosi cistica: a che punto siamo?" Meeting annuale Associazione Lombarda Fibrosi Cistica. Milano 16 Aprile 2016 "Diagnosi problematiche di fibrosi cistica" La Fibrosi cistica: dall'età pediatrica all'età adulta. II° Conferenza Regionale di Organizzazione. Ancona 21 Maggio 2016. "CFTR2, CFTR3 e diagnosi" XII Congresso Nazionale della Società Italiana per lo studio della Fibrosi Cistica, Salerno 10 Novembre 2016. "A clinician's point of view on the FFC-network's research" 14th Convention of FFC investigators in cystic fibrosis, 24-26 November 2016, Garda (Verona) "Vere e false novità nella terapia della fibrosi cistica" A Tu Per Tu Con Lo Specialista ... 27 Aprile 2017 Irccs Burlo Garofolo, Trieste "Fase 1 nella fibrosi cistica" Master aspetti regolatori, brevettuali ed economici dello sviluppo dei farmaci e dei dispositivi medici Roma 16-21 ottobre 2017 "L'adulto con fibrosi cistica" Pneumotrieste 16-18 Aprile 2018 "Comunicare la diagnosi di una fibrosi cistica che cambia" XIII Congresso Nazionale Della Società Italiana Per Lo Studio Della Fibrosi Cistica Napoli, 22-25 Novembre 2017 "Infezioni in fibrosi cistica Nuove frontiere terapeutiche e possibili nuovi scenari" Diagnostica e Terapia delle Infezioni Opportunistiche Genova 20-21 Giugno 2018 "Il percorso della ricerca farmacologica ed il ruolo dei Centri FC: una storia di successo o un modello in crisi?" VI Forum italiano sulla Fibrosi Cistica, 2018 "Outcomes Of Spontaneous Application Of Carrier Screening For Cystic Fibrosis: Follow-Up Of Its Effects On Birth Prevalence, Neonatal Screening And Reproductive Behaviour Of Carrier Couples**"** 16th Convention of FFC investigators in CF. Novembre 2015. Verona "Fibrosi Cistica: il futuro" Senato della Repubblica, 25 anni di tutele e diritti della legge 548/93. Roma 3 Aprile 2019 "Update su epidemiologia nella fibrosi cistica dell'adulto" La fibrosi cistica 2.0. Roma 4-5 Aprile 2019 "CFTR: il gene dalle 1000 e più facce" XV Congresso Nazionale Della Società Italiana Per Lo Studio Della Fibrosi Cistica Milano, 10 - 12 Ottobre 2019 "Fibrosi cistica: la transizione nell'età adulta" XX Congresso Nazionale della Pneumologia Italiana, Firenze 14-15 Novembre 2019

	"Genetica e destino: un rapporto immutabile?" Forum Lega Italiana Fibrosi Cistica, Montesilvano, 22-24 Novembre 2019